Palisade Bio (PALI) vs Sutro Biopharma (STRO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Sutro Biopharma (STRO) has outperformed Palisade Bio (PALI) over the past year, gaining 2.4% versus a loss of 60.6%. Over five years, STRO leads with a -94.7% price change compared with -100.0% for PALI. Palisade Bio is the larger company by market cap ($150.7 million vs $142.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PALI | STRO |
|---|---|---|
| Share price | $0.8399 | $8.60 |
| Market cap | $150.74M | $142.77M |
| 1-day change | -9.24% | -1.38% |
| YTD return | -64.26% | -25.67% |
| 1-year return | -60.57% | +2.38% |
| 5-year return | -99.95% | -94.68% |
| P/E ratio (TTM) | 0.91 | — |
| EPS (TTM) | $0.92 | $-12.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $102.48M |
| Revenue growth (YoY) | — | +65.18% |
| Net income (latest FY) | $-16.78M | $-191.09M |
| Operating margin | — | -154.53% |
| Net margin | — | -186.45% |
| 52-week high | $2.86 | $43.85 |
| 52-week low | $0.8381 | $7.15 |
| Distance from 52-week high | -70.63% | -80.39% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +935.84% | +419.65% |
| Average volume | 3.19M | 304.90K |
| Shares outstanding | 179.28M | 16.60M |
| Employees | 14 | 129 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- STRO has outperformed PALI by 62.9 percentage points over the past year.
About Palisade Bio
PALI stock →Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 14 employees
About Sutro Biopharma
STRO stock →Sutro Biopharma, Inc. operates as an oncology company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 129 employees
PALI vs STRO FAQ
Which is bigger, Palisade Bio or Sutro Biopharma?
Palisade Bio (PALI) is larger, with a market capitalization of $150.74M compared with $142.77M for Sutro Biopharma (STRO).
Which stock has performed better over the past year, PALI or STRO?
STRO returned +2.38% over the past 12 months, compared with -60.57% for PALI (price return, excluding dividends). Past performance does not predict future results.
Are Palisade Bio and Sutro Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.